The 70-gene profile and chemotherapy benefit in 1,600 breast cancer patients. J Clin Oncol 27:15s, 2009 (suppl; abstr 512).
[35] van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999-2009. [36] Paik S, Shak S, Tang G, et al. A multigene assay to
predict
recurrence
of
tamoxifen-treated,
node-negative breast cancer. N Engl J Med. 2004; 351:2817-2826.
[37] Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001; 93:684-690.
[38] Fisher B, Dignam J, Wolmark N, et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptorpositive breast cancer. J Natl Cancer Inst. 1997; 89:1673-1682.
[39] Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative,
estrogen receptor-positive breast cancer. J Clin Oncol. 2006; 24:3726-3734.
[40] Sunil S. Badve, Frederick L. et al. Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory. J Clin Oncol 2008；26:2473-2481.
[41] Albain K, Barlow W, Shak S, et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal, node-positive, ER-positive breast cancer (S8814, INT0100). San Antonio Breast Cancer Symposium: Abstract 10, 2007.
[42] Goldstein LJ, Gray R, Badve S, et al. Prognostic utility
of
the
21-gene
assay
in
hormone
receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008; 26:4063-4071.
[43] Ivo A. Olivotto, Chris D. Bajdik, Peter M. Ravdin, et al. Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer. J Clin Oncol 2005；23:2716-2725.
[44] NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2009.